Ligand Pharmaceuticals (LGND) Cash & Current Investments (2010 - 2026)

Ligand Pharmaceuticals has disclosed Cash & Current Investments across 17 years of filings, most recently posting $779.4 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $779.4 million, up 273.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $779.4 million (up 273.1% YoY), and the FY2025 annual result was $190.6 million, down 25.61% from the prior year.
• Cash & Current Investments came in at $779.4 million for Q1 2026 at Ligand Pharmaceuticals, up from $190.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $779.4 million in Q1 2026 to a low of $74.8 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $211.9 million (2022), against an average of $265.0 million.
• Across the five-year window, Cash & Current Investments sank 62.44% in 2022 and soared 788.97% in 2025, its largest moves.
• Ligand Pharmaceuticals' Cash & Current Investments stood at $211.9 million in 2022, then fell by 19.62% to $170.3 million in 2023, then surged by 50.41% to $256.2 million in 2024, then dropped by 25.61% to $190.6 million in 2025, then soared by 309.01% to $779.4 million in 2026.
• The last three Cash & Current Investments figures came in at $779.4 million (Q1 2026), $190.6 million (Q4 2025), and $664.5 million (Q3 2025), per Business Quant data.